Immunology for
a Better Future
Learn More
Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.
Learn More
We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.
Learn More
Advancing Therapeutic
Solutions
Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.
Learn More
Focused on Improving
Lives
We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.
Learn More
Key Highlights
AIM ImmunoTech Provides Update Regarding Annual Meeting
AIM Will Convene Annual Meeting on December 1st and then Adjourn Until December 29th to Give Delaware Court Additional Time to Deliver Ruling in Activist Group Litigation OCALA, Fla. - AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced...
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 27, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today...
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
No severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the last subject has completed treatment in the Company's Phase 2 study...